- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer Disease
- Interventions
- SSRI
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 50 Years and older
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Condition Directory
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 15, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
707
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 397–408 of 707 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Alzheimer Disease
- Interventions
- LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more
- Conditions
- Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Interventions
- Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
- Drug
- Lead sponsor
- Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
- Federal
- Eligibility
- Not listed
- Enrollment
- 8,680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dementia, Alzheimer Disease
- Interventions
- SMARRT Intervention, Health Education Intervention
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 70 Years to 89 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alzheimer Disease
- Interventions
- Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
- Interventions
- Mobile Phone Application Assessments, Standard Assessments
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Alzheimer Disease, Physical Activity
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Cognitive Impairment, Dementia, Aging
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 2,262 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- All Subjects
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Alzheimer Disease, Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD), Vascular Contributions to Cognitive Impairment and Dementia (VCID), Mixed Etiology Dementias (MED), Mild Cognitive Impairment (MCI)
- Interventions
- Problem Solving Training
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- College Station, Texas • Dallas, Texas • Edinburg, Texas
- Conditions
- Mild Cognitive Impairment
- Interventions
- PrecivityAD
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Alzheimer Disease
- Interventions
- ACU193, Placebo
- Drug
- Lead sponsor
- Acumen Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Anaheim, California • Newport Beach, California + 14 more
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.